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Background: For screening a library of enzyme mutants, an efficient and cost-effective method for reliable
assay of enzyme activity and a decision method for safe recognition of mutants of higher activity are needed. The
comparison of activity concentrations of mutants in lysates of transformed Escherichia coli cells against a threshold
is unsafe to recognize mutants of higher activity due to variations of both expression levels of mutant proteins and
lysis efficiency of transformed cells. Hence, by a spectrophotometric method after verification to measure uricase
activity, specific activity calculated from the level of total proteins in a lysate was tested for recognizing a mutant of
higher activity.
Results: During uricase reaction, the intermediate 5-hydroxyisourate interferes with the assay of uric acid
absorbance, but the measurement of absorbance at 293 nm in alkaline borate buffer was reliable for measuring
uricase initial rates within a reasonable range. The level of total proteins in a lysate was determined by the Bradford
assay. Polyacrylamide gel electrophoresis analysis supported different relative abundance of uricase mutant proteins
in their lysates; activity concentrations of uricase in such lysates positively correlated with levels of total proteins.
Receiver-operation-curve analysis of activity concentration or specific activity yielded area-under-the-curve close to
1.00 for recognizing a mutant with > 200% improvement of activity. For a mutant with just about 80%
improvement of activity, receiver-operation-curve analysis of specific activity gave area-under-the-curve close to 1.00
while the analysis of activity concentration gave smaller area-under-the-curve. With the mean plus 1.4-fold of the
standard deviation of specific activity of a starting material as the threshold, uricase mutants whose activities were
improved by more than 80% were recognized with higher sensitivity and specificity.
Conclusion: Specific activity calculated from the level of total proteins is a favorable index for recognizing an
enzyme mutant with small improvement of activity.
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Evolution biotechnology is powerful to discover new en-
zymes in chemical biology [1-4]. The practice of evolution
biotechnology requires an efficient and cost-effective ana-
lytical method for reliable assay of catalytic capacities of
mutants, and a suitable decision method for recognizing
mutants of higher catalytic capacity as positive candidates
or potential hits. In general, there should be mutagenesis
on multiple sites of an enzyme to significantly improve
the catalytic capacity; random mutagenesis of all possible
sites of an enzyme will produce a huge library to burden
the screening process. Hence, the design of focused li-
braries of mutants of an enzyme via mutagenesis of just a
few sites is favorable, but a suitable decision method is
required to recognize positive candidates with small
improvement of catalytic capacity [5-8].
Catalytic capacity of an enzyme is measurable only with
its sample of the highest purity. To practice the screening
of a library, however, crude enzymes of mutants in lysates
of transformed Escherichia coli cells after induced expres-
sion have to be employed as samples to measure activities
for comparison against a suitable threshold derived from
that of the starting material [6-13]. In general, the concen-
tration of an enzyme in a lysate reflected by its activity
(denoted as activity concentration hereafter) or specific
activity can be utilized as activity index for comparison.
The comparison of activity concentration of a mutant
in its lysate against a threshold to recognize positive
candidates is utilized in classical decision methods, but
the variations in levels of mutant proteins due to differ-
ences in the inoculation quantity of a clone, amplifica-
tion efficiency of the clone, induced expression levels
and/or lysis efficiency of transformed cells reduce the
safety for recognizing positive candidates. The com-
parison of specific activity may facilitate recognizing a
mutant of small improvement of activity, but is prevented
from practicing by the lack of efficient methods for
selective assay of a mutant protein in its lysate. Alterna-
tively, the quantification of total proteins in a lysate by a
conventional protein assay may yield a practical specific
activity to facilitate recognizing a positive candidate,
but the effectiveness of this approach has not been
reported yet.
Uricases are biodrugs to treat refractory gout [14-17],
and pivotal analytical tools to measure serum uric acid
[18]. Any application of uricase requires its catalytic
capacity as high as possible [19-21], but available wildtype
uricases all have low catalytic capacity. To date, uricase
catalytic mechanisms are unknown and evolution biotech-
nology is practical to obtain uricase mutants of higher
catalytic capacity. Uricase catalyzes the oxidation of uric
acid into hydrogen peroxide and 5-hydroxyisourate (HIU)
that spontaneously decomposes into allantoin of no ab-
sorbance at wavelengths over 280 nm [22]. Peroxidase-coupled and ferrous/ferric ion-mediated assays of hydro-
gen peroxide can measure uricase activity by quantifying
absorbance or fluorescence [23-27], but require the
termination of uricase reaction and thus reduce efficiency
for screening uricase mutants. Notably, there must be a
large portion of uric acid leftover in reaction solution to
measure uricase initial rates; residual uric acid in uricase
reaction solutions usually interferes with such methods
for quantifying hydrogen peroxide [28,29]. On the other
hand, uric acid has a strong absorbance peak at 293 nm
and the assay of uric acid absorbance has the highest
efficiency and the lowest cost for screening uricase
mutants. However, HIU has an absorption peak around
302 nm and may interfere with the assay of uricase initial
rates by measuring uric acid absorbance [30,31]. There-
fore, the screening of uricase mutants needs a decision
method to safely recognize positive candidates and the
verification of the assay of uric acid absorbance for mea-
suring uricase activity.
The uricase of Bacillus fastidious is a promising
biodrug for treating refractory gout and a suitable tool
for serum uric acid assay [32-34]; we cloned this uricase
gene and obtained some mutants with small differences
in catalytic capacities. In this report, the assay of uric
acid absorbance at 293 nm was verified for measuring
uricase activity; specific activity calculated from the level
of total proteins in a lysate was tested as the index for
comparison against a threshold for recognizing a positive
candidate.Materials and methods
Reagents, chemicals and apparatus
Uric acid was from Sigma-Aldrich. Boric acid, tri-
(hydroxylmethyl)-aminomethane (Tris), and sodium borate
were common reagents of analytical grade or better. Water
was re-stilled before use. pET28a vector carrying on the
coding sequence for the wildtype intracellular uricase from
Bacillus fastidious A.T.C.C. 29604 was that we used previ-
ously (gene id FJ393559, protein id ACR09749.1) [33]. By
site-directed mutagenesis or the substitution of a fragment
with an intended sequence, uricase mutants with different
sequences of the N-terminus and/or mutagensis of the
unique cysteine residue into aspartic acid residue were
generated (Additional file 1: sheet 1, mutant sequences
and summary; these vectors were constructed via tech-
nical service provided by Taihe Biotechnolyg Co. Ltd,
Beijing 100070, China). Escherichia coli cell strain BL21
(DE3) as the host to harvest vectors of such uricases for
induced expression was provided by Sangon Biotech-
nology (Shanghai, China). DEAE-cellulose was from
Whatman (Kent, UK). Xinmao UV 7504 spectrophotome-
ter (http://www.china-xinmao.com) was used throughout
the work.
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uricase
The expression of the wildtype uricase followed that
described previously [33]. After the induced expression
with isopropyl-β-D-thiogalactoside (IPTG) for 18 h at
16°C, Escherichia coli cells BL21 (DE3) were harvested,
and lysed by sonication; the soluble uricase was purified
over two consecutive DEAE-cellulose chromatography
via the elution with 0.10 M Tris–HCl at pH 8.0 plus a
linear gradient of NaCl from 0 to 0.40 M. Fractions
with the activities over 6.0 U·mg-1 protein were pooled,
and dialyzed against 50.0 mM sodium borate buffer
(Na2B4O7·10H2O) at pH 9.2 for 24 h at 4°C with several
changes of the buffer, and then stored at 4°C before use.
Uricase activities were calibrated at 25°C with 0.075 mM
uric acid in borate buffer at pH 9.2 by measuring
absorbance at 293 nm. One unit of uricase oxidized one
micromole uric acid per min calculated with the extinc-
tion coefficient of 11.5 (mM) -1·cm-1 [33,35].Monitor of uricase reaction and estimation of Michaelis-
Menten constant
Borate buffer was prepared with a required ratio of 50.0
mM sodium borate (Na2B4O7·10H2O) to 0.20 M boric
acid [35]. Each reaction mixture in a total of 0.80 mL
contained 50 μL uricase solution and 0.75 ml solution of
uric acid in the borate buffer at an indicated pH. The solu-
tions of uric acid were pre-incubated at (25 ± 0.5)°C for 20
min before use and prepared every day. Reaction was initi-
ated by the addition of uricase solution; absorbance was
recorded in an isolated small room air-conditioned at
25°C, after a lag time of 20 s at proper intervals within
5 min, unless otherwise stated [36,37]. The wildtype intra-
cellular uricase of Bacillus fastidious A.T.C.C. 29604 has
Michaelis-Menten constant (Km) over 0.20 mM and uric
acid over 0.40 mM is needed for estimating Km [30,31];
the uricase of Asahi-Kasei (http://www.asahi-kasei.co.jp/
shindan/eng/list/index.html) has Km below 50 μM and the
use of uric acid below 0.10 mM is sufficient for estimating
its Km. Hence, to test the estimation of Km, the absorbance
of uric acid was measured at 308 nm with the recombin-
ant wildtype uricase of Bacillus fastidious A.T.C.C. 29604,
but at 293 nm with the uricase from Asahi-Kasei, for the
maximal absorbance of uric acid within the measurable
range of the spectrophotometer. Initial rates were average
velocities when uric acid consumption percentages were
below 10% after 40 s since reaction initiation. Km was
estimated by regression analyses according to Lineweaver-
Burk plot with determination coefficients over 0.97.Assay of total proteins
Protein quantity in a lysate was measured by the Bradford
method [38]. All operations completely followed thosedescribed in the publication. Specific activity was cal-
culated with the level of total proteins in a lysate as
determined.
Operation procedure for screening uricase mutants
After purification via two consecutive DEAE-Cellulose
chromoatography followed by preparative polyacrylamide
gel electrophoresis (PAGE), uricase catalytic capacity was
the highest specific activity determined with 75 μM uric
acid in the borate buffer at pH 9.2. Four uricase mutants
of the bacterial uricase as active homotetramers were uti-
lized and denoted as candidate A, B, C and D with their
catalytic capacities in a descent order. Among those four
candidates, any two uricases were randomly selected into
a pair. For such pairs of uricases, the ratios of their
catalytic capacities ranged from about 1.3 to about 4.0.
Their sequences and kinetic parameters were provided in
Additional file 1 (sheet 1, mutant sequences and summary).
To mimic the procedure of screening, the pET28a
vector of each mutant was transformed into Escherichia
coli BL21 (DE3) cells. From each vector, a total of 30
clones on a selective plate with karnamycin were picked
one-by-one; every clone was transferred into 1.0-mL
selective medium in a 5.0-ml Ependorf tube for cultiva-
tion at 37°C for 3 h. Then, IPTG for final 1.0 mM was
added to induce the expression of uricase for 18 h at
16°C. Cells from each tube were harvested by centrifuga-
tion and lyzed by sonication treatment in ice-water bath
at 150 W for 2.0 min (continuous treatment for 2.5 s at
intervals of 2.5 s, Ningbo Xinzhi Biomedicine LTD,
Zhejiang, China; http://www.csb17.cn/Photo_Show.asp?
InfoId=231, model JY92-II sonics cell lysis equipment);
insoluble materials were removed by centrifugation at
10,000 rpm for 10 min again. The untransformed E. coli
BL21 cells contained no endogenous uricase and thus
activities of uricases in cell lysates were directly mea-
sured. In each clear lysate, uricase activity after proper
dilution was measured in duplicate by monitoring UV
absorbance at 293 nm with 75 μM uric acid in 0.20 M
sodium borate buffer at pH 9.2. The dilution ratio for
each candidate was optimized. Abundance of uricase
protein in such lysates was examined by SDS-PAGE
followed by staining proteins, and further by PAGE to
visualize the active forms of uricases via the staining of
activity (the staining reaction produces the insoluble
visible chromogen through the coupled peroxidase
action on a chromogenic substrate and hydrogen pero-
xide released by the action of uricase on uric acid) [39].
Data processing and recognition of a mutant of higher
activity
Coefficient of variation (CV) was deduced from standard
deviation (SD) and mean, and was compared by F-test to
examine homoscedasticity. Statistical comparisons and
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Normality of data was examined with Shapiro-Wilk test
incorporated in SPSS 17.0.
In each pair of two uricases, the one of lower catalytic
capacity is taken as the starting material and the other
of higher catalytic capacity is designated as the positive
candidate. Two methods were used for the recognition
of a positive candidate in a pair with its activity mea-
sured in a lysate. Firstly, statistical comparison of ave-
rages of activity indexes in lysates of two uricases in a
pair was used. Secondly, data in each pair were analyzed
by receiver-operation-curve (ROC) analysis with SPSS
17.0 to determine the area-under-the-curve (AUC)
[40,41]. The response of AUCs to ratios of catalytic
capacities of paired uricases was examined. The minimal
ratio in the catalytic capacities of a pair of uricases for
an AUC of about 1.00 was selected; from ROC of this
pair of two uricase, a threshold was selected for the
sensitivity of 90% and specificity as close to 90% as
possible. Such a threshold was normalized with respect
to the mean and SD of the starting material to test its
universal applicability to other pairs of uricases.
Results and discussion
Verification of the assay of uric acid absorbance for
measuring initial rate
For screening mutants, uricase activities are reflected by
change rates of uric acid absorbance during initial rate
reaction. The interference of HIU with the assay of
uricase initial rate by measuring uric acid absorbance
depends on extinction coefficient and dynamic levels ofFigure 1 Interference from HIU with the assay of absorbance at 308 n
action at 25°C. a. Effects of activities on interference in 0.10 M Tris–HCl bu
buffer at pH 7.4 c. Effects of reaction pH on interference in 0.10 M Tris–HCl
interference in 0.20 M borate buffer with final uricase activity at 103 U/L.HIU. When uric acid consumption percentages are low
enough for initial rate reaction, there will be no interfe-
rence from HIU with the assay of uricase initial rate and
thus a linear decrease of uric acid absorbance if HIU
levels remain steady, or else, there will be interference
from HIU with the assay of uricase initial rate and thus
a nonlinear decrease of uric acid absorbance. Steady-
state level of HIU and its lag time are determined by its
production and decomposition rates. Steady-state of
uricase reaction requires a lag time of about 40 s [35,36].
When the consumption of uric acid is within 10%,
nonlinear decrease of uric acid absorbance after a lag
time of 40 s directly supports that HIU levels do not
achieve steady-state. If steady-state of HIU is achieved
after so long lagging periods that the consumption
percentages of uric acid exceed the limits for initial rate
reaction, there will be inaccurate initial rates of uricases
and such deviations are more pronounced with uricases
of higher Km. Any factor affecting the production and
decomposition rates of HIU including uricase activity,
the use of Tris–HCl buffer or borate buffer, and reaction
pH, will alter the steady-state levels of HIU and thus its
interference with the assay of uricase initial rate by
measuring uric acid absorbance [30,31]. On the other
hand, the wavelength to quantify uric acid absorbance
also alters extinction coefficient of HIU and thus its
interference with the assay of uricase initial rates. The
absorbance peak of uric acid locates at 293 nm while
that of HIU is around 302 nm [30,31]. The bacterial
uricase has Km over 0.20 mM for uric acid [32,33]; the
highest level of uric acid should be about 0.4 mM tom after the lag time of 10 s for 0.30 mM uric acid under uricase
ffer at pH 7.4 b. Effects of activities on interference in 0.20 M borate
buffer with final uricase activity at 103 U/L d. Effects of reaction pH on
Figure 2 Effects of uricase activities on Km estimated by
measuring absorbance at 308 nm in 0.20 M borate buffers at
25°C. Final uric acid concentrations ranged from 0.10 to 0.50 mM at
pH 9.2 or 8.2, and from 0.070 to 0.33 mM at pH 7.4. Results were
from at least three independent assays with CVs below 12%. Uricase
activities were those calibrated with 0.075 mM uric acid at the
indicated reaction pH. * indicated P < 0.05 versus that at lower
uricase activities by Student t-test.
Figure 3 PAGE analyses of proteins in lysates of four uricase
mutants. (a) SDS-PAGE and staining of protein bands. (b) PAGE
followed by the staining of protein bands (left side) and uricase
activity (right side).
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308 nm, absorbance for uric acid at 0.4 mM is below
1.200 and measurable with common spectrophotome-
ters; the interference from HIU with the assay of uricase
initial rate by measuring uric acid absorbance should be
more manifest at 308 nm than at 293 nm. The bacterial
uricase is thus an ideal model to test the existence andsolution of the interference from HIU with the assay of
uricase initial rate. Moreover, uricase activities will alter
the interference from HIU with initial rates and thus Km
estimated via Lineweaver-Burk plot analysis of initial
rates, which violates the facts with common enzymes.
Hence, the interference from HIU with the assay of
uricase initial rates by uric acid absorbance is examined
based on: (a) effects of uricase activities, reaction buffers
and pH values on nonlinear decreases of absorbance of
uric acid when its consumption percentages are below
10%, (b) effects of wavelengths to quantify uric acid
absorbance on nonlinear decreases of absorbance of uric
acid when its consumption percentages are below 10%,
and (c) the effects of uricase activities on Km.
In Tris–HCl buffer at 7.4, the interference from HIU
with the absorbance of 0.30 mM uric acid at 308 nm
was detected as a continuous increase rather than
decrease in absorbance till a peak at about 100 s since
reaction initiation, even the consumption of uric acid
was within 10%; the use of a higher uricase activity
produced a larger increase in absorbance at 308 nm after
100 s since reaction initiation (Figure 1). These results
Table 1 Uricase activities at 0.075 mM uric acid and
protein levels in lysates (n = 30)
Candidates/parameters A B C D
Total proteins by the Bradford assay 0.63 0.66 0.65 0.66
(0.09) (0.10) (0.15) (0.09)
Activity concentration 0.30 0.28 0.18 0.033
(0.07) (0.06) (0.05) (0.004)
P for normality of AC by
shapiro-Wilk test
0.104 0.182 0.439 0.282
Correlation coefficient (R) >0.63 >0.81 >0.84 >0.44
Specific activity 0.49 0.43 0.28 0.050
(0.09) (0.05) (0.05) (0.006)
P for normality of SA by Shapiro-Wilk test <0.001 0.310 0.972 0.031
Numbers in parentheses were SD. Correlation coefficient was that for the
association of activity concentrations with levels of total proteins. R > 0.361
and > 0.464 indicated P < 0.05 and P < 0.01 for the association of activity
concentrations with proteins levels, respectively. SA: specific activity; AC:
activity concentration.
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within 100 s since reaction initiation. The interference
from HIU with uric acid absorbance in Tris–HCl buffers
was alleviated by the increase in reaction pH or the use
of magnesium ion (Additional file 2: Figure S1, S2). After
reaction initiation at 103 U/L uricase, there were no
detectable increases in absorbance at 293 nm but tiny
increases in absorbance at 308 nm with 0.12 mM uric
acid in Tris–HCl buffer at pH 7.4 (Additional file 2:
Figure S3), and there were also no increases in absorb-
ance at 308 nm with 0.30 mM uric acid in 0.20 M
sodium borate buffers at pH 7.4 (Figure 1); those results
supported the interference from HIU with uric acid
absorbance is weaker at 293 nm than at 308 nm and is
even negligible in borate buffers at both wavelengths. At
400 U/L uricase, uric acid concentration after the lag
time of 20 s in the borate buffer at pH 7.4 was smaller
than 0.27 mM, but there were still no increases in
absorbance at 308 nm. No increases in absorbance at
308 nm during uricase reaction were detected in borate
buffers at higher pH. On the other hand, when activities













A-B 1.37 1.07 0.559 1.19 0.799
B-C 1.58 1.54 0.895 1.56 0.985
A-C 2.15 1.67 0.921 1.82 1.000
C-D 1.90 5.45 1.000 5.60 1.000
B-D 3.00 8.48 1.000 8.60 1.000
A-D 4.10 9.09 1.000 9.92 1.000
Based on error propagation, the experimental ratios in pairs had CVs about
20%. SA: specific activity; AC: activity concentration.measuring absorbance at 308 nm in borate buffers
decreased to stable values (Figure 2). The use of a higher
reaction pH enabled the estimation of such a stable Km
at higher uricase activities. For Asahi-Kasei uricase with
Km of about 30 μM, the highest uric acid levels were
below 0.10 mM so that uric acid absorbance can be
measured at 293 nm in borate buffers to determine
initial rates for estimating its Km; there were no changes
of Km over a wide range of uricase activities. Moreover,
by measuring absorbance at 293 nm with 0.075 mM uric
acid in borate buffer at pH 9.2, initial rates linearly
responded to uricase quantities ranging from 0.6 to
about 12 U/L when absorbance was monitored at 5-s
intervals. Repetitive assays for uricase activities from 3.0
U/L to 12 U/L with a pooled lysate showed CVs below
5.5% (n = 11).
Taken together, the assay of absorbance of uric acid at
293 nm in alkaline borate buffers is reliable for measu-
ring uricase initial rates within a reasonable range.
Recognition of a mutant of higher activity
To recognize positive candidates in a library, a decision
method should have sensitivity and specificity as high as
possible. One-fold or 100% improvement of catalytic cap-
acity of a mutant already makes sense and the recognition
of such a mutant is a challenge. Hence, four uricases with
ratios of catalytic capacities from about 1.3-fold to about
4-fold were employed as models to test the potential
solutions to the challenge.
The abundance of uricase proteins in lysates was
examined at first. With the same quantities of total
proteins for analyses, band density of four uricases was
different after SDS-PAGE followed by staining of protein
bands, or after PAGE followed by staining of uricase
activity (Figure 3). The averages of total proteins inFigure 4 ROC analysis of the pair of uricase with ratio of about
1.80 for their catalytic capacities and associations of
normalized cutoffs (×0.1) with 1-specificity. SA: specific activity;
AC: activity concentration
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ences, but their activity concentrations displayed positive
associations with the levels of total proteins in lysates;
those results supported the concern on negative impacts
of variations of the levels of mutant proteins in lysates
on the recognition of positive candidates. Activity con-
centration of uricases in lysates basically followed
normal distribution, but specific activities of most
candidates displayed non-normal distribution (Table 1).
Candidate D had the lowest abundance and the lowest
specific activity. The ratios of specific activities among
candidate A, B and C showed no significant deviations
from those of catalytic capacities, but the ratios of
specific activities of candidate A, B and C to that of
candidate D were more than twice of those of catalytic
capacities, respectively (Table 2). Such large deviations
in ratios of specific activities of the three uricase
mutants to candidate D from those of their catalytic
capacities should be associated with the lower abun-
dance of candidate D in its lysate. Hence, the variations
in the abundance of mutant proteins in lysates should be
considered carefully.
To reveal the differences between the comparison of
activity concentration and specific activity for recog-
nizing positive candidates, ROC analyses were per-
formed [40,41]. Clearly, the smaller differences in
catalytic capacities of paired uricases led to smaller
AUCs by comparing either activity concentration or spe-
cific activity (Table 2). When ratios of catalytic capacities
of a pair of uricases were over 3.0, the comparison of
either activity index consistently yielded AUCs of 1.000.
For uricase pairs with ratios of their catalytic capacities
below 2.0, the comparison of specific activity gave higher
AUCs than the comparison of activity concentration
(Table 2). Hence, for screening uricase mutants, the
comparison of specific activity calculated from the levels
of total proteins in lysates is favorable for recognizing
positive candidates of small improvement of activity.
By the comparison of specific activity to recognize a
positive candidate, a practical threshold is required. The
ratio of specific activity between candidate A and C was
over 1.7 with either crude enzymes or purified enzymes
(Additional file 1: sheet 1: mutant sequences and
summary), and their activity concentrations and specific
activities exhibited consistent CVs (Table 1). The prac-
tical threshold for the recognition of a positive candidate
was investigated with this pair of uricases. For ROC
analysis of the recognition of candidate A as a positive
candidate against candidate C, the deviations of the
preset cutoffs from the mean of the starting material
were divided by the SD of the starting material for
plotting against 1-specificty to observe the association of
decision sensitivity with the preset cutoffs (Figure 4). For
no less than 90% specificity to recognize the positivecandidate in this uricase pair, the mean of specific acti-
vity plus 1.4-fold of the SD of the starting material can
be a practical threshold (Additional file 1: sheet 2: ROC
analysis of activity). By using such a threshold to other
uricase pairs, the comparison of specific activity always
gave higher sensitivity to identify positive candidates
than the comparison of activity concentration. Hence,
the comparison of specific activity calculated from the
levels of total proteins against a suitable threshold is
more favorable for recognizing positive candidates with
small improvement of catalytic capacity.Conclusion
For screening uricase mutants, the assay of UV absorb-
ance of uric acid at 293 nm is effective to measure uricase
activities within a reasonable range in alkaline borate
buffers. To recognize a mutant of small improvement of
catalytic capacity, specific activity calculated from total
proteins in a lysate is an index better than activity concen-
tration; a practical threshold for comparison to recognize
a positive candidate can be the mean plus 1.4-fold SD of
specific activities of the starting material.Additional files
Additional file 1: The following additional data are available with
the online version of this paper. Sheet 1: mutant sequences and
summary; Sheet 2: ROC analysis of activity.
Additional file 2: The following additional data are available with
the online version of this paper. Figure S1. Effects of magnesium ion
on the interference from HIU in Tris–HCl buffer at pH 7.4; Figure S2.
Effects of magnesium ion on the interference from HIU in Tris–HCl buffer
at pH 8.9; Figure S3. Interference from HIU with A293 and A308 for uric
acid in Tris–HCl buffer at pH 7.4.Abbreviations
AUC: Area-under-the-curve; BSA: Beef serum albumin; HIU: 5-hydroisourate;
IPTG: Isopropyl-β-D-thiogalactoside; Km: Michaelis-Menten constant;
OVA: Ovalumin; ROC: Receiver-operation-curve; Tris: Tri-(hydroxylmethyl)-
aminomethane.
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